The technology, which is being developed by MicrofluidX, could help manufacturers overcome major bottlenecks in the development of cell and gene therapies, as well as reduce the time and costs associated with bringing such treatments to market.
Whilst cell and gene therapies offer promising treatment options in disease areas with unmet clinical needs, reliable methods are still needed to manufacture these therapies to commercial levels.
